Klaviyo Q1 Beats but CFO Exit Sends Shares Down 15%

NEW YORK, May 24 —

Klaviyo reported a first-quarter earnings beat on May 5, disclosed a CFO transition in the same filing, and watched its stock fall 15% anyway. The shares now sit at $14.87, just over half the consensus analyst price target of $29.23, while co-CEO Andrew Bialecki has continued selling shares at prices that have fallen nearly 25% since late March.

The Beat Nobody Caught

Klaviyo's Q1 results were strong. EPS of $0.16 against a $0.13 consensus estimate is the kind of number that typically produces a relief rally. The company also filed a Regulation FD guidance update alongside its May 5 8-K — management put revised estimates on the record, not just on an earnings call.

The problem was what else was in that filing. Item 5.02 of the same 8-K disclosed a CFO departure. Investors got four things at once: a genuine EPS beat, raised guidance, a departing finance chief, and a Q2 outlook that fell short of expectations. The stock fell 15%.

The CFO Problem

CFO departures are common enough that they rarely move a stock by themselves. A CFO departure nested inside an earnings release, with no successor named, is harder to absorb alongside a guidance raise. Whether the timing was deliberate or administrative, the company chose not to wait for a quieter window.

The structural problem is this: analysts are now building models off guidance that a departing finance chief just approved. Whether the incoming CFO will stand behind those assumptions, or revise them on arrival, is an open question. At $14.87 against a consensus target of $29.23, analyst models imply a 97% gain from current price. Gaps that wide close one of two ways: the stock rises, or analysts cut their targets. A CFO transition is not, by itself, a reason for analysts to cut. It is a reason for investors to ask whether the guidance numbers survive the handoff.

The Selling Curve

The insider data complicates the picture. Under a pre-scheduled 10b5-1 trading plan, co-CEO Andrew Bialecki sold 200,000 shares at $19.42 on March 31, another 200,000 at $18.63 on April 7, 200,000 shares across two tranches at prices ranging from $14.46 to $14.97 on May 12, and another 200,000 shares at $14.88 on May 19. The selling cadence has been consistent. The prices have not.

Across all Klaviyo executives, trailing 90-day insider activity totals $17.73 million in sales with zero open-market purchases. Amanda Whalen, the outgoing CFO per Form 4 filings, sold shares in April and again in May, the second batch coming after the departure announcement. The legal case for 10b5-1 plans is straightforward — they let insiders sell on a predetermined schedule, removing any informational advantage. What they do not explain is why no one at Klaviyo has bought a single share on the open market while the stock trades at roughly half the consensus analyst target.

What Changes the Thesis

At 14.4x forward earnings on a $4.45 billion company, Klaviyo's multiple does not explain a $14.87 share price for a business that just beat estimates and raised guidance. The $0.16 Q1 EPS confirms the company is profitable. The $14.87-to-$29.23 spread is one of the wider price-to-target gaps in mid-cap SaaS.

That gap resolves on two events: a named CFO successor who publicly affirms the guidance range, and Q2 results that confirm the Q1 beat was not a peak. If both arrive, the current discount to analyst targets looks hard to justify. If Q2 disappoints or the CFO seat stays empty, the pattern of insider selling at declining prices becomes harder to explain away with a 10b5-1 defense.

For now, the stock sits at $14.87, essentially where Bialecki sold his last tranche. The next checkpoint is Q2 earnings. Until then, the distance between that price and the $29.23 analyst target is a question management will need to answer with actions rather than guidance language.

Run the free Klaviyo, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why did Klaviyo stock fall 15% after earnings?

Klaviyo reported Q1 EPS of $0.16, beating the $0.127 consensus estimate. The same May 5 8-K disclosed a CFO transition under Item 5.02. The Q2 outlook also disappointed investors. Those three factors together drove the 15% single-session decline.

Is Klaviyo stock undervalued right now?

At $14.87, the stock trades at 14.4x forward earnings and roughly half the $29.23 consensus analyst target, implying a 96% gain on the analyst view. Whether the stock closes that gap or analysts cut their targets depends on Q2 results and whether the CFO transition disrupts guidance — neither question was settled by the Q1 beat.

Why is Klaviyo's co-CEO selling so much stock?

Andrew Bialecki's sales operate under a 10b5-1 pre-scheduled trading plan, a legal structure that lets executives sell shares on a fixed schedule without acting on inside information. Over the trailing 90 days, he has sold shares in tranches at prices ranging from $19.42 down to $14.88. No open-market purchases have been recorded to offset the selling.

What happened to Klaviyo's CFO?

Klaviyo's May 5 8-K disclosed a CFO transition under Item 5.02, covering the departure and appointment of principal officers. The disclosure landed in the same filing as Q1 earnings results. It contributed to the 15% share decline that followed.

What is Klaviyo's current valuation?

Klaviyo's market capitalization is approximately $4.45 billion at a current share price of $14.87. The stock trades at a 14.4x forward price-to-earnings ratio, against a consensus analyst price target of $29.23.